25 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28435528	24	Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.	Kezar Life Sciences
25006746	85	Structure-based design ofß1i orß5i specific inhibitors of human immunoproteasomes.	Leiden Institute of Chemistry and Netherlands Proteomics Centre
24524217	65	Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.	Hokkaido University
32189500	56	LMP2 Inhibitors as a Potential Treatment for Alzheimer's Disease.	University of Kentucky
27563406	128	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.	Roche Pharma Research and Early Development
30639896	42	Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.	Hangzhou Institute of Innovative Medicine
30611983	48	Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.	Zhejiang University
30380863	196	Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).	Kezar Life Sciences
31521028	67	Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.	Hangzhou Xixi Hospital
30964987	13	Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.	University of Kentucky
30587447	3	Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.	Purdue University
30657666	263	Structure-Based Design of Inhibitors Selective for Human Proteasome ?2c or ?2i Subunits.	Leiden Institute of Chemistry and Netherlands Proteomics Centre
31801019	5	Novel Cell-Penetrating Peptide Conjugated Proteasome Inhibitors: Anticancer and Antifungal Investigations.	University of Auckland
30455150	10	Tetradehydrohalicyclamine B, a new proteasome inhibitor from the marine sponge Acanthostrongylophora ingens.	Kumamoto University
17249727	8	Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete.	Intermed Discovery Gmbh (Imd)
15780623	39	Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.	Numazu Bio-Medical Research Institute
7608891	7	Potent inhibitors of proteasome.	Cephalon
11992770	19	Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.	Novartis Pharma
29339252	124	Structure-based design of human immuno- and constitutive proteasomes inhibitors.	Universit£
29652143	22	Reviewing Hit Discovery Literature for Difficult Targets: Glutathione Transferase Omega-1 as an Example.	Monash University